Sun Pharma and Zydus Pharmaceuticals have initiated recalls of their medications in the US due to manufacturing and quality concerns, as flagged by the US Food and Drug Administration (USFDA).
Sun Pharma’s New Jersey-based unit is recalling 9,840 bottles of Morphine Sulfate extended-release tablets due to failed dissolution specifications, according to the US health regulator’s latest enforcement report. The company initiated a Class II recall on February 6, 2025, which applies to products that could lead to temporary or medically reversible health issues but are unlikely to cause serious adverse effects.
Meanwhile, Zydus Pharmaceuticals (USA) Inc is recalling over 38,000 vials of Nelarabine Injection, a medication used in the treatment of certain types of cancer, due to impurities and degradation issues. The company initiated two separate recalls on February 13, 2025, affecting 36,978 vials of Nelarabine Injection (250mg/50mL) and an additional 1,893 vials of the same drug.
USFDA’s Continued Scrutiny on Indian Pharma
The recalls highlight the growing regulatory challenges Indian pharmaceutical companies face in the US, a key market for generic drugmakers. Indian firms play a crucial role in supplying medicines to the US healthcare system, with four out of every ten prescriptions in the US in 2022 being filled by Indian manufacturers.
Industry estimates indicate that medications from Indian firms saved the US healthcare system $219 billion in 2022 alone, and $1.3 trillion over the past decade. With generic drugs from India projected to save an additional $1.3 trillion in the next five years, maintaining high quality and regulatory compliance is critical for sustaining market dominance.
Also read: Sun Pharma Acquires US Oncology Firm for $355M
India’s Pharma Sector Faces Quality Control Challenges
While Indian pharmaceutical firms have established themselves as leaders in affordable and high-quality generic medicines, frequent USFDA warnings and recalls raise concerns about compliance with global standards.
Both Sun Pharma and Zydus Pharmaceuticals have not yet released official statements regarding the recalls. However, industry experts suggest that such regulatory actions underscore the need for stronger quality control measures and more rigorous internal compliance processes to mitigate risks associated with recalls.
With the US being the largest market for Indian drugmakers, maintaining a strong regulatory track record will be crucial for companies looking to expand their footprint in global healthcare.
